Today, Amgen shared its 2025 first quarter earnings report. Amgen’s more than 28,000 employees are united by our mission to serve patients. We harness the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller, and longer.
"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," said Bob Bradway, Chairman and Chief Executive Officer, Amgen.
The infographic below provides more highlights about the company’s 2025 first quarter results.
Additional details can be found in the earnings press release. Please see forward-looking statements.
A webcast of the earnings call found on Amgen’s Investors page.
